Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

678 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
Dauvilliers Y, Lecendreux M, Lammers GJ, Franco P, Poluektov M, Caussé C, Lecomte I, Lecomte JM, Lehert P, Schwartz JC, Plazzi G. Dauvilliers Y, et al. Among authors: schwartz jc. Lancet Neurol. 2023 Apr;22(4):303-311. doi: 10.1016/S1474-4422(23)00036-4. Lancet Neurol. 2023. PMID: 36931805 Clinical Trial.
Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.
Dauvilliers Y, Craig SE, Bonsignore MR, Barbé F, Verbraecken J, Asin J, Georgiev O, Tiholov R, Caussé C, Lecomte JM, Schwartz JC, Lehert P, Randerath W, Pépin JL; HAROSA III Study Group. Dauvilliers Y, et al. Among authors: schwartz jc. J Sleep Res. 2024 Oct 8:e14373. doi: 10.1111/jsr.14373. Online ahead of print. J Sleep Res. 2024. PMID: 39377364
Exploratory Phase II Trial to Evaluate the Safety and the Antiepileptic Effect of Pitolisant (BF2.649) in Refractory Partial Seizures, Given as Adjunctive Treatment During 3 Months.
Collart Dutilleul P, Ryvlin P, Kahane P, Vercueil L, Semah F, Biraben A, Schwartz JC, De Seze J, Hirsch E, Collongues N. Collart Dutilleul P, et al. Among authors: schwartz jc. Clin Neuropharmacol. 2016 Jul-Aug;39(4):188-93. doi: 10.1097/WNF.0000000000000159. Clin Neuropharmacol. 2016. PMID: 27223666 Clinical Trial.
Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model.
Kasteleijn-Nolst Trenité D, Parain D, Genton P, Masnou P, Schwartz JC, Hirsch E. Kasteleijn-Nolst Trenité D, et al. Among authors: schwartz jc. Epilepsy Behav. 2013 Jul;28(1):66-70. doi: 10.1016/j.yebeh.2013.03.018. Epub 2013 May 8. Epilepsy Behav. 2013. PMID: 23665640 Clinical Trial.
Direct and indirect effects of CYTOR lncRNA regulate HIV gene expression.
Kuzmina A, Sadhu L, Hasanuzzaman M, Fujinaga K, Schwartz JC, Fackler OT, Taube R. Kuzmina A, et al. Among authors: schwartz jc. PLoS Pathog. 2024 Apr 25;20(4):e1012172. doi: 10.1371/journal.ppat.1012172. eCollection 2024 Apr. PLoS Pathog. 2024. PMID: 38662769 Free PMC article.
678 results